Autopsy report · NCT01545050

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

“due to sponsor decision”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 1 year 6 months before it stopped.
• 72 participants enrolled.
• Results were posted on the registry 8 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

CSL Behring

Sponsor type

Industry

Conditions

Crohn's Disease

Interventions

Placebo matching with BMS-945429; Placebo matching with BMS-945429; Placebo matching with BMS-945429; Placebo matching with BMS-945429; BMS-945429; BMS-945429

Participants

72

Sites

56

Countries

Austria, Canada, Czechia, France, Germany, Hong Kong, Hungary, India, Israel, Italy, Mexico, Netherlands and more

Trials that died the same way

• Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND1 Mutations
  “Due to the sponsor circumstances and external reasons” (87% match in meaning)
• OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer
  “Due to sponsor request” (87% match in meaning)
• AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE
  “Sponsor Decision” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.